Skip to main content
Top
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer

Authors: Meghan L Verschoor, Gurmit Singh

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

Ovarian cancer is characterized by high rates of metastasis and therapeutic resistance. Many chemotherapeutic agents rely on the induction of oxidative stress to cause cancer cell death, thus targeting redox regulation is a promising strategy to overcome drug resistance.

Methods

We have used a tetracycline-inducible Ets-1 overexpression model derived from 2008 ovarian cancer cells in the present study. To examine the role of Ets-1 in glutathione regulation we have measured intracellular reactive oxygen species and glutathione levels, as well as glutathione peroxidase enzyme activity. Glutathione synthesis was limited using transsulfuration or Sxc- pathway blocking agents, and glutamate release was measured to confirm Sxc- blockade. Cell viability following drug treatment was assessed via crystal violet assay. Oxidative stress was induced through glucose oxidase treatment, which produces hydrogen peroxide by glucose oxidation. The protein expressions of redox-related factors were measured through western blotting.

Results

Overexpression of Ets-1 was associated with decreased intracellular ROS, concomitantly with increased intracellular GSH, GPX antioxidant activity, and Sxc- transporter activity. Under basal conditions, inhibition of the transsulfuration pathway resulted in decreased GSH levels and GPX activity in all cell lines, whereas inhibition of Sxc- by sulfasalazine decreased GPX activity in Ets-1-expressing cells only. However, under oxidative stress the intracellular GSH levels decreased significantly in correlation with increased Ets-1 expression following sulfasalazine treatment.

Conclusions

In this study we have identified a role for proto-oncogene Ets-1 in the regulation of intracellular glutathione levels, and examined the effects of the anti-inflammatory drug sulfasalazine on glutathione depletion using an ovarian cancer cell model. The findings from this study show that Ets-1 mediates enhanced Sxc- activity to increase glutathione levels under oxidative stress, suggesting that Ets-1 could be a promising putative target to enhance conventional therapeutic strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coleman RL, Monk BJ, Sood AK, Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013, 10: 211-224. 10.1038/nrclinonc.2013.5PubMedCentralCrossRefPubMed Coleman RL, Monk BJ, Sood AK, Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013, 10: 211-224. 10.1038/nrclinonc.2013.5PubMedCentralCrossRefPubMed
2.
3.
go back to reference Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N: Ovarian cancer stem cells. Neoplasma. 2012, 59: 747-755. 10.4149/neo_2012_094CrossRefPubMed Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N: Ovarian cancer stem cells. Neoplasma. 2012, 59: 747-755. 10.4149/neo_2012_094CrossRefPubMed
4.
go back to reference Guddati AK: Ovarian cancer stem cells: elusive targets for chemotherapy. Med Oncol. 2012, 29: 3400-3408. 10.1007/s12032-012-0252-6CrossRefPubMed Guddati AK: Ovarian cancer stem cells: elusive targets for chemotherapy. Med Oncol. 2012, 29: 3400-3408. 10.1007/s12032-012-0252-6CrossRefPubMed
5.
go back to reference Aguilar-Gallardo C, Rutledge EC, Martinez-Arroyo AM, Hidalgo JJ, Domingo S, Simon C: Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev. 2012, 8: 994-1010. 10.1007/s12015-011-9344-5CrossRefPubMed Aguilar-Gallardo C, Rutledge EC, Martinez-Arroyo AM, Hidalgo JJ, Domingo S, Simon C: Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev. 2012, 8: 994-1010. 10.1007/s12015-011-9344-5CrossRefPubMed
6.
go back to reference Ahmed N, Abubaker K, Findlay J, Quinn M: Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 2010, 10: 268-278. 10.2174/156800910791190175CrossRefPubMed Ahmed N, Abubaker K, Findlay J, Quinn M: Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 2010, 10: 268-278. 10.2174/156800910791190175CrossRefPubMed
7.
go back to reference Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, Tsang BK: Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci. 2012, 1271: 58-67. 10.1111/j.1749-6632.2012.06734.xPubMedCentralCrossRefPubMed Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, Tsang BK: Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci. 2012, 1271: 58-67. 10.1111/j.1749-6632.2012.06734.xPubMedCentralCrossRefPubMed
8.
go back to reference Wilson LA, Yamamoto H, Singh G: Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther. 2004, 3: 823-832.PubMed Wilson LA, Yamamoto H, Singh G: Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther. 2004, 3: 823-832.PubMed
9.
go back to reference Verschoor ML, Verschoor CP, Singh G: Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers. Cancer & Metabolism. 2013, 1: 17-10.1186/2049-3002-1-17. 10.1186/2049-3002-1-17CrossRef Verschoor ML, Verschoor CP, Singh G: Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers. Cancer & Metabolism. 2013, 1: 17-10.1186/2049-3002-1-17. 10.1186/2049-3002-1-17CrossRef
10.
go back to reference Verschoor ML, Wilson LA, Verschoor CP, Singh G: Ets-1 regulates energy metabolism in cancer cells. PLoS One. 2010, 5: e13565- 10.1371/journal.pone.0013565PubMedCentralCrossRefPubMed Verschoor ML, Wilson LA, Verschoor CP, Singh G: Ets-1 regulates energy metabolism in cancer cells. PLoS One. 2010, 5: e13565- 10.1371/journal.pone.0013565PubMedCentralCrossRefPubMed
11.
go back to reference Burhans WC, Heintz NH: The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med. 2009, 47: 1282-1293. 10.1016/j.freeradbiomed.2009.05.026CrossRefPubMed Burhans WC, Heintz NH: The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med. 2009, 47: 1282-1293. 10.1016/j.freeradbiomed.2009.05.026CrossRefPubMed
12.
go back to reference Singh S, Khan AR, Gupta AK: Role of glutathione in cancer pathophysiology and therapeutic interventions. J Exp Ther Oncol. 2012, 9: 303-316.PubMed Singh S, Khan AR, Gupta AK: Role of glutathione in cancer pathophysiology and therapeutic interventions. J Exp Ther Oncol. 2012, 9: 303-316.PubMed
13.
go back to reference Ryu CS, Kwak HC, Lee JY, Oh SJ, Phuong NT, Kang KW, Kim SK: Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. Biochem Pharmacol. 2013, 85: 197-206. 10.1016/j.bcp.2012.10.021CrossRefPubMed Ryu CS, Kwak HC, Lee JY, Oh SJ, Phuong NT, Kang KW, Kim SK: Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. Biochem Pharmacol. 2013, 85: 197-206. 10.1016/j.bcp.2012.10.021CrossRefPubMed
14.
go back to reference Syed Alwi SS, Cavell BE, Donlevy A, Packham G: Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. Cell Stress Chaperones. 2012, 17: 529-538. 10.1007/s12192-012-0329-3PubMedCentralCrossRefPubMed Syed Alwi SS, Cavell BE, Donlevy A, Packham G: Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. Cell Stress Chaperones. 2012, 17: 529-538. 10.1007/s12192-012-0329-3PubMedCentralCrossRefPubMed
15.
go back to reference Guha P, Dey A, Sen R, Chatterjee M, Chattopadhyay S, Bandyopadhyay SK: Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. J Pharmacol Exp Ther. 2011, 336: 206-214. 10.1124/jpet.110.171983CrossRefPubMed Guha P, Dey A, Sen R, Chatterjee M, Chattopadhyay S, Bandyopadhyay SK: Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. J Pharmacol Exp Ther. 2011, 336: 206-214. 10.1124/jpet.110.171983CrossRefPubMed
16.
17.
go back to reference Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N: Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer. 1997, 79: 521-527. 10.1002/(SICI)1097-0142(19970201)79:3<521::AID-CNCR14>3.0.CO;2-5CrossRefPubMed Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N: Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer. 1997, 79: 521-527. 10.1002/(SICI)1097-0142(19970201)79:3<521::AID-CNCR14>3.0.CO;2-5CrossRefPubMed
18.
go back to reference Lo M, Ling V, Low C, Wang YZ, Gout PW: Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol. 2010, 17: 9-16.PubMedCentralPubMed Lo M, Ling V, Low C, Wang YZ, Gout PW: Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol. 2010, 17: 9-16.PubMedCentralPubMed
19.
go back to reference Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N: The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Mini Rev Med Chem. 2008, 8: 1095-1105. 10.2174/138955708785909934CrossRefPubMed Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N: The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Mini Rev Med Chem. 2008, 8: 1095-1105. 10.2174/138955708785909934CrossRefPubMed
20.
go back to reference Verschoor ML, Wilson LA, Singh G: Mechanisms associated with mitochondrial-generated reactive oxygen species in cancer. Can J Physiol Pharmacol. 2010, 88: 204-219. 10.1139/Y09-135CrossRefPubMed Verschoor ML, Wilson LA, Singh G: Mechanisms associated with mitochondrial-generated reactive oxygen species in cancer. Can J Physiol Pharmacol. 2010, 88: 204-219. 10.1139/Y09-135CrossRefPubMed
21.
go back to reference Alipov G, Nakayama T, Ito M, Kawai K, Naito S, Nakashima M, Niino D, Sekine I: Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology. 2005, 46: 202-208. 10.1111/j.1365-2559.2005.02059.xCrossRefPubMed Alipov G, Nakayama T, Ito M, Kawai K, Naito S, Nakashima M, Niino D, Sekine I: Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology. 2005, 46: 202-208. 10.1111/j.1365-2559.2005.02059.xCrossRefPubMed
22.
go back to reference Buggy Y, Maguire TM, McGreal G, McDermott E, Hill AD, O’Higgins N, Duffy MJ: Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer. 2004, 91: 1308-1315. 10.1038/sj.bjc.6602128PubMedCentralCrossRefPubMed Buggy Y, Maguire TM, McGreal G, McDermott E, Hill AD, O’Higgins N, Duffy MJ: Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer. 2004, 91: 1308-1315. 10.1038/sj.bjc.6602128PubMedCentralCrossRefPubMed
23.
go back to reference Chang XZ, Yu J, Zhang XH, Yin J, Wang T, Cao XC: Enhanced expression of trophinin promotes invasive and metastatic potential of human gallbladder cancer cells. J Cancer Res Clin Oncol. 2009, 135: 581-590. 10.1007/s00432-008-0492-1CrossRefPubMed Chang XZ, Yu J, Zhang XH, Yin J, Wang T, Cao XC: Enhanced expression of trophinin promotes invasive and metastatic potential of human gallbladder cancer cells. J Cancer Res Clin Oncol. 2009, 135: 581-590. 10.1007/s00432-008-0492-1CrossRefPubMed
24.
go back to reference Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM: Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res. 2001, 7: 551-557.PubMed Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM: Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res. 2001, 7: 551-557.PubMed
25.
go back to reference Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Trope CG, Kristensen GB, Bryne M, Reich R: Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol. 2001, 25: 1493-1500. 10.1097/00000478-200112000-00004CrossRefPubMed Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Trope CG, Kristensen GB, Bryne M, Reich R: Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol. 2001, 25: 1493-1500. 10.1097/00000478-200112000-00004CrossRefPubMed
26.
go back to reference Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Sakaguchi H, Tamaya T: Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology. 2004, 66: 420-428. 10.1159/000079491CrossRefPubMed Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Sakaguchi H, Tamaya T: Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology. 2004, 66: 420-428. 10.1159/000079491CrossRefPubMed
27.
go back to reference Katayama S, Nakayama T, Ito M, Naito S, Sekine I: Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. Histol Histopathol. 2005, 20: 119-126.PubMed Katayama S, Nakayama T, Ito M, Naito S, Sekine I: Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. Histol Histopathol. 2005, 20: 119-126.PubMed
28.
go back to reference Saeki H, Oda S, Kawaguchi H, Ohno S, Kuwano H, Maehara Y, Sugimachi K: Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer. 2002, 98: 8-13. 10.1002/ijc.10163CrossRefPubMed Saeki H, Oda S, Kawaguchi H, Ohno S, Kuwano H, Maehara Y, Sugimachi K: Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer. 2002, 98: 8-13. 10.1002/ijc.10163CrossRefPubMed
29.
go back to reference Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y: Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res. 2001, 101: 242-247. 10.1006/jsre.2001.6279CrossRefPubMed Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y: Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res. 2001, 101: 242-247. 10.1006/jsre.2001.6279CrossRefPubMed
30.
go back to reference Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG: Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene. 2002, 21: 8506-8509. 10.1038/sj.onc.1206040CrossRefPubMed Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG: Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene. 2002, 21: 8506-8509. 10.1038/sj.onc.1206040CrossRefPubMed
31.
go back to reference Wilson LA, Gemin A, Espiritu R: Singh G: ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element. FASEB J. 2005, 19: 2085-2087.PubMed Wilson LA, Gemin A, Espiritu R: Singh G: ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element. FASEB J. 2005, 19: 2085-2087.PubMed
32.
go back to reference Azad MB, Chen Y, Gibson SB: Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal. 2009, 11: 777-790. 10.1089/ars.2008.2270CrossRefPubMed Azad MB, Chen Y, Gibson SB: Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal. 2009, 11: 777-790. 10.1089/ars.2008.2270CrossRefPubMed
33.
go back to reference Higuchi Y, Yoshimoto T: Arachidonic acid converts the glutathione depletion-induced apoptosis to necrosis by promoting lipid peroxidation and reducing caspase-3 activity in rat glioma cells. Arch Biochem Biophys. 2002, 400: 133-140. 10.1006/abbi.2002.2784CrossRefPubMed Higuchi Y, Yoshimoto T: Arachidonic acid converts the glutathione depletion-induced apoptosis to necrosis by promoting lipid peroxidation and reducing caspase-3 activity in rat glioma cells. Arch Biochem Biophys. 2002, 400: 133-140. 10.1006/abbi.2002.2784CrossRefPubMed
34.
go back to reference Hayes JD, McMahon M: NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 2009, 34: 176-188. 10.1016/j.tibs.2008.12.008CrossRefPubMed Hayes JD, McMahon M: NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 2009, 34: 176-188. 10.1016/j.tibs.2008.12.008CrossRefPubMed
35.
go back to reference Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK, Chen GF: Regulation of hypoxia inducible factor-1alpha expression by the alteration of redox status in HepG2 cells. J Exp Clin Cancer Res. 2011, 30: 61- 10.1186/1756-9966-30-61PubMedCentralCrossRefPubMed Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK, Chen GF: Regulation of hypoxia inducible factor-1alpha expression by the alteration of redox status in HepG2 cells. J Exp Clin Cancer Res. 2011, 30: 61- 10.1186/1756-9966-30-61PubMedCentralCrossRefPubMed
36.
go back to reference Badawi Y, Ramamoorthy P, Shi H: Hypoxia-inducible factor 1 protects hypoxic astrocytes against glutamate toxicity. ASN Neuro. 2012, 4: 231-241. 10.1042/AN20120006CrossRefPubMed Badawi Y, Ramamoorthy P, Shi H: Hypoxia-inducible factor 1 protects hypoxic astrocytes against glutamate toxicity. ASN Neuro. 2012, 4: 231-241. 10.1042/AN20120006CrossRefPubMed
37.
go back to reference Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Folsch UR, Schafer H: Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer. 2003, 104: 469-476. 10.1002/ijc.10963CrossRefPubMed Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Folsch UR, Schafer H: Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer. 2003, 104: 469-476. 10.1002/ijc.10963CrossRefPubMed
38.
go back to reference Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW, Wang YZ: The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol. 2009, 64: 463-472. 10.1007/s00280-008-0894-4CrossRefPubMed Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW, Wang YZ: The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol. 2009, 64: 463-472. 10.1007/s00280-008-0894-4CrossRefPubMed
39.
go back to reference Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE: Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res. 2007, 67: 3878-3887. 10.1158/0008-5472.CAN-06-3191CrossRefPubMed Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE: Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res. 2007, 67: 3878-3887. 10.1158/0008-5472.CAN-06-3191CrossRefPubMed
40.
go back to reference Guo W, Zhao Y, Zhang Z, Tan N, Zhao F, Ge C, Liang L, Jia D, Chen T, Yao M: Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett. 2011, 312: 55-61. 10.1016/j.canlet.2011.07.024CrossRefPubMed Guo W, Zhao Y, Zhang Z, Tan N, Zhao F, Ge C, Liang L, Jia D, Chen T, Yao M: Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett. 2011, 312: 55-61. 10.1016/j.canlet.2011.07.024CrossRefPubMed
41.
go back to reference Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, Wang YZ: Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007, 67: 162-171. 10.1002/pros.20508CrossRefPubMed Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, Wang YZ: Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007, 67: 162-171. 10.1002/pros.20508CrossRefPubMed
42.
go back to reference Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR: Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy. 2007, 53: 210-217. 10.1159/000100812CrossRefPubMed Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR: Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy. 2007, 53: 210-217. 10.1159/000100812CrossRefPubMed
43.
go back to reference Andrews PA, Albright KD: Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 1992, 52: 1895-1901.PubMed Andrews PA, Albright KD: Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 1992, 52: 1895-1901.PubMed
44.
go back to reference Sharma MK, Seidlitz EP, Singh G: Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun. 2010, 391: 91-95. 10.1016/j.bbrc.2009.10.168CrossRefPubMed Sharma MK, Seidlitz EP, Singh G: Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun. 2010, 391: 91-95. 10.1016/j.bbrc.2009.10.168CrossRefPubMed
45.
go back to reference Rahman I, Kode A, Biswas SK: Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 2006, 1: 3159-3165.CrossRefPubMed Rahman I, Kode A, Biswas SK: Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 2006, 1: 3159-3165.CrossRefPubMed
Metadata
Title
Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer
Authors
Meghan L Verschoor
Gurmit Singh
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-138

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine